There are 2789 resources available
1650P - Adoption and early clinical outcomes of atezolizumab (atezo) + carboplatin and etoposide (CE) in patients with extensive-stage small cell lung cancer (ES-SCLC) in the real-world (RW) setting
Presenter: David Chun Cheong Tsui
Session: ePoster Display
1651P - Phase I study of ramucirumab in combination with irinotecan plus cisplatin in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)
Presenter: Toshiaki Takahashi
Session: ePoster Display
1652P - Safety of simultaneously performed radiotherapy in patients with small cell lung cancer undergoing atezolizumab treatment
Presenter: Julia Galuba
Session: ePoster Display
1653P - Assessment of PD-L1 expression on circulating tumor cells (CTCs) and immune cells in peripheral blood of patients with small cell lung cancer (SCLC)
Presenter: Maria A Papadaki
Session: ePoster Display
1654P - A phase Ib/II study of the dual MDMX/MDM2 inhibitor, ALRN-6924, for the prevention of chemotherapy-induced myelosuppression
Presenter: Zoran Andric
Session: ePoster Display
1655P - Real-world outcome of patients with relapsed or refractory small cell lung cancer treated with checkpoint inhibitors in Tertiary Care Centers across Germany
Presenter: Jan Stratmann
Session: ePoster Display
1656P - Germline mutations in DNA damage repair genes in patients with small cell lung cancer
Presenter: Yu Feng
Session: ePoster Display
1657P - Anlotinib plus irinotecan or docetaxel in small-cell lung cancer (SCLC) relapsed within six months: Updated results from a single-arm phase II study
Presenter: Bing Xia
Session: ePoster Display
1607P - Trends in cancer imaging by indication, care setting, and hospital type during the COVID-19 pandemic and recovery
Presenter: Ottavia Zattra
Session: ePoster Display
1608P - The impact of COVID-19 on the delivery of systemic anti-cancer treatment at Guy’s Cancer Centre
Presenter: Saoirse Dolly
Session: ePoster Display
Resources:
Abstract